Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award: Canada Graduate Scholarships

McGill University

$105,000.00

Developing Differentiation Regulators for Acute Myeloid Leukemia using RNA Therapeutics

EF 2023-24

Résumé
Acute myeloid leukemia (AML) is the leading cause of adult leukemia deaths in Canada. AML is a rapidly progressing blood cancer in which the bone marrow produces immature blood cells that cannot carry out the function of healthy cells, leading to symptoms such as anemia, infection, and bleeding. Even with contemporary therapies, only ~ 30% of cases are cured. The goal of this project is to develop a novel strategy for the treatment of AML using a new class of drugs: RNA therapeutics. RNA drugs work by directly altering the expression of currently "undruggable" gene targets, such as transcription factors. The expression and activity of key transcriptions factors are essential for the successful maturation of immune cells and low levels of such factors contribute to the progression of the disease. Therefore, we plan to design, validate, and characterize RNA duplexes capable of activating these key targets inactivated or downregulated in most AML patients. We will then go on to validate a liposomal delivery vehicle capable of selectively delivering these RNA drugs to leukemia cells; further improving the safety and efficacy of this novel treatment. Promising candidates will be tested in validated animal models of AML as a proof-of-concept for the application of RNA therapeutics for the treatment of AML. By combining RNA targeted therapies with current therapeutics, we can further improve and personalize the treatment of currently extremely difficult to cure AMLs, moving towards a future with more survivors.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
497037
Name
Kovecses Olivia
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Developing Differentiation Regulators for Acute Myeloid Leukemia using RNA Therapeutics
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Acute Myeloid Leukemia; Differentiation Therapy; Nucleic Acid Therapeutics; Personalized Medicine; Small Activating Rna; Transcription Factor Networks
Abstract
Acute myeloid leukemia (AML) is the leading cause of adult leukemia deaths in Canada. AML is a rapidly progressing blood cancer in which the bone marrow produces immature blood cells that cannot carry out the function of healthy cells, leading to symptoms such as anemia, infection, and bleeding. Even with contemporary therapies, only ~ 30% of cases are cured. The goal of this project is to develop a novel strategy for the treatment of AML using a new class of drugs: RNA therapeutics. RNA drugs work by directly altering the expression of currently "undruggable" gene targets, such as transcription factors. The expression and activity of key transcriptions factors are essential for the successful maturation of immune cells and low levels of such factors contribute to the progression of the disease. Therefore, we plan to design, validate, and characterize RNA duplexes capable of activating these key targets inactivated or downregulated in most AML patients. We will then go on to validate a liposomal delivery vehicle capable of selectively delivering these RNA drugs to leukemia cells; further improving the safety and efficacy of this novel treatment. Promising candidates will be tested in validated animal models of AML as a proof-of-concept for the application of RNA therapeutics for the treatment of AML. By combining RNA targeted therapies with current therapeutics, we can further improve and personalize the treatment of currently extremely difficult to cure AMLs, moving towards a future with more survivors.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Kovecses, Olivia
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~